Hikma to host investor and analyst conference call
London, 10 February 2016 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing pharmaceuticals company, announces that Hikma management will host a conference call for investors and analysts today at 12:30pm UK time to discuss the revised terms for its previously announced acquisition of Roxane Laboratories.
The conference call can be accessed by dialling +44 (0)20 3139 4830, and the participant PIN code is 25497247#. An audio replay of the conference call will also be made available approximately two hours after the conclusion of the call. The audio replay can be accessed by dialling +44 (0)20 3426 2807 and entering the PIN code 668223#.
Said Darwazah, Chairman and Chief Executive Officer of Hikma, and Khalid Nabilsi, Chief Financial Officer of Hikma, will host the call.
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/ +44 7776 477050
Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/ +44 7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of US$1,489 million and profit attributable to shareholders of US$299 million.
This information is provided by RNS